- Nachrichtendetail
-
13.05.2024 07:39:16 - dpa-AFX: *REGENERON: FDA ACCEPTS FOR PRIORITY REVIEW SBLA FOR DUPIXENT FOR CHRONIC RHINOSINUSITIS WITH NASAL POLYPOSIS
Copyright(c) 2024 RTTNews.com. All Rights Reserved
Copyright RTT News/dpa-AFX
Copyright RTT News/dpa-AFX
| Name | WKN | Börse | Kurs | Datum/Zeit | Diff. | Diff. % | Geld | Brief | Erster | Schluss | |
|---|---|---|---|---|---|---|---|---|---|---|---|
 |
SANOFI SA INHABER EO 2 | 920657 | Frankfurt | 103,500 | 24.09.24 08:20:00 | +0,200 | +0,19% | 103,360 | 103,660 | 103,500 | 103,300 |
|
REGENERON PHARMAC.DL-,001 | 881535 | Frankfurt | 976,200 | 24.09.24 08:15:03 | -8,000 | -0,81% | 976,200 | 988,000 | 976,200 | 984,200 |
